Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00095199
Status:
COMPLETED
Last Update Posted:
2012-10-15
First Post:
2004-11-01
Brief Title:
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy
Status:
COMPLETED
Status Verified Date:
2012-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is a multicenter open-label randomized Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer NSCLC after failure of an initial platinum-based chemotherapy Patients will receive either Docetaxel or Pemetrexed as chemotherapy at the investigators choice Within each chemotherapy group patients will be randomized to receive Cetuximab plus chemotherapy or chemotherapy alone Cetuximab Pemetrexed or Pemetrexed alone Cetuximab Docetaxel or Docetaxel alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CP02-0452 | OTHER | ImClone | None |
| I4E-MC-JXBC | OTHER | None | None |